A pharmaceutical formulation with high stability and dissolution, comprises aripipazole or a pharmaceutical acceptable salt thereof, at least a filler selected from the group consisting of mannitol, isomalt and sorbitol, at least a disintegrant selected from the group consisting of crosspovidone, crosscarmellose sodium and sodium starch glycolate, a pharmaceutical acceptable binder and a pharmaceutical acceptable lubricant.